Stocks
Allogene Therapeutics Financial Statements (ALLO) |
||||||||||
| Allogene Therapeuticssmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 27.02.2020 | 25.02.2021 | 23.02.2022 | 28.02.2023 | 14.03.2024 | 13.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.000 | 0.000 | 38.5 | 0.243 | 0.095 | 0.130 | |||
| Operating Income, bln rub | -202.0 | -258.2 | -255.8 | -335.4 | -314.5 | -284.9 | ||||
| EBITDA, bln rub | ? | -184.9 | -258.2 | -255.8 | -335.4 | -287.0 | -270.7 | |||
| Net profit, bln rub | ? | -184.6 | -233.5 | -244.8 | -329.8 | -327.3 | -290.1 | |||
| OCF, bln rub | ? | -137.4 | -115.1 | -184.8 | -220.5 | -237.7 | -227.0 | |||
| CAPEX, bln rub | ? | 50.8 | 66.0 | 21.4 | 5.19 | 1.52 | 0.489 | |||
| FCF, bln rub | ? | -188.1 | -181.1 | -206.3 | -225.7 | -239.2 | -227.5 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 202.0 | 258.2 | 294.3 | 335.7 | 314.6 | 281.4 | ||||
| Cost of production, bln rub | 5.03 | 11.5 | 13.1 | 16.7 | 242.9 | 65.6 | ||||
| R&D, bln rub | 144.5 | 193.0 | 220.2 | 256.4 | 242.9 | 211.4 | ||||
| Interest expenses, bln rub | 0.000 | 0.000 | 0.000 | 17.1 | 0.000 | 0.366 | ||||
| Assets, bln rub | 717.8 | 1 228 | 1 039 | 817.1 | 642.8 | 586.4 | ||||
| Net Assets, bln rub | ? | 629.0 | 1 080 | 916.4 | 665.9 | 512.2 | 461.4 | |||
| Debt, bln rub | 51.3 | 53.8 | 69.9 | 95.1 | 95.1 | 95.8 | ||||
| Cash, bln rub | 588.9 | 1 032 | 809.5 | 576.5 | 448.7 | 384.9 | ||||
| Net debt, bln rub | -537.5 | -978.3 | -739.6 | -481.3 | -353.6 | -289.0 | ||||
| Ordinary share price, rub | 26.0 | 25.2 | 14.9 | 6.29 | 3.21 | 2.97 | ||||
| Number of ordinary shares, mln | 101.1 | 120.4 | 135.8 | 143.1 | 156.9 | 169.1 | ||||
| Market cap, bln rub | 2 626 | 3 038 | 2 026 | 900 | 504 | 502 | ||||
| EV, bln rub | ? | 2 088 | 2 060 | 1 287 | 419 | 150 | 213 | |||
| Book value, bln rub | 629 | 1 080 | 916 | 666 | 512 | 461 | ||||
| EPS, rub | ? | -1.83 | -1.94 | -1.80 | -2.30 | -2.09 | -1.72 | |||
| FCF/share, rub | -1.86 | -1.50 | -1.52 | -1.58 | -1.52 | -1.35 | ||||
| BV/share, rub | 6.22 | 8.97 | 6.75 | 4.65 | 3.26 | 2.73 | ||||
| EBITDA margin, % | ? | -664.6% | -138 045% | -302 156% | -208 215% | |||||
| Net margin, % | ? | -636.1% | -135 726% | -344 489% | -223 140% | |||||
| FCF yield, % | ? | -7.17% | -5.96% | -10.2% | -25.1% | -47.5% | -45.3% | |||
| ROE, % | ? | -29.3% | -21.6% | -26.7% | -49.5% | -63.9% | -62.9% | |||
| ROA, % | ? | -25.7% | -19.0% | -23.6% | -40.4% | -50.9% | -49.5% | |||
| P/E | ? | -14.2 | -13.0 | -8.28 | -2.73 | -1.54 | -1.73 | |||
| P/FCF | -14.0 | -16.8 | -9.82 | -3.99 | -2.11 | -2.21 | ||||
| P/S | ? | 52.6 | 3 705 | 5 303 | 3 864 | |||||
| P/BV | ? | 4.18 | 2.81 | 2.21 | 1.35 | 0.98 | 1.09 | |||
| EV/EBITDA | ? | -11.3 | -7.98 | -5.03 | -1.25 | -0.52 | -0.79 | |||
| Debt/EBITDA | 2.91 | 3.79 | 2.89 | 1.43 | 1.23 | 1.07 | ||||
| R&D/CAPEX, % | 284.6% | 292.6% | 1 027% | 4 939% | 16 023% | 43 227% | ||||
| CAPEX/Revenue, % | 55.7% | 2 136% | 1 596% | 376.2% | ||||||
| Allogene Therapeutics shareholders | ||||||||||
